Researchers discover potential breakthrough treatment for rare condition Céline Dion lives with

Researchers have identified a potential revolutionary treatment for stiff-person syndrome (SPS), a rare autoimmune condition affecting fewer than 2 in every million people in the U.S. The therapy, developed with $2 million in funding from the Céline Dion Foundation, uses CAR T-cell therapy—a cancer treatment repurposed to target misbehaving B-cells in SPS patients. The trial, led by Dr. Amanda Piquet, involved 26 adults with SPS. Four months after treatment, all participants showed improved walking speed, and eight of 12 who previously relied on walking aids no longer needed them. Piquet noted a 46% improvement in mobility among patients, describing the results as 'incredible.' CAR T-cell therapy works by removing T-cells from the patient’s blood, modifying them in a lab to attack B-cells, and then reintroducing them to reset the immune system. Piquet explained that the therapy could offer long-lasting relief, though further long-term studies are required to confirm durability. The findings were presented at the 2026 American Academy of Neurology Annual Meeting in April. While Piquet emphasized the promising early results, she cautioned against premature declarations of a cure, stating that long-term monitoring is essential to understand the therapy’s sustained effects. Céline Dion, who publicly disclosed her SPS diagnosis in 2022, has supported the research through her foundation. The condition causes progressive muscle stiffness, spasms, and mobility challenges, including difficulties with breathing, swallowing, and speaking. The therapy’s success marks a significant step forward for SPS patients, offering hope for a disease-free future without ongoing medication.